Evaxion Biotech AS (EVAX) - Net Assets
Based on the latest financial reports, Evaxion Biotech AS (EVAX) has net assets worth $9.53 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($19.38 Million) and total liabilities ($9.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Evaxion Biotech AS (EVAX) strategic investment index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.53 Million |
| % of Total Assets | 49.18% |
| Annual Growth Rate | 26.8% |
| 5-Year Change | -47.47% |
| 10-Year Change | N/A |
| Growth Volatility | 189.45 |
Evaxion Biotech AS - Net Assets Trend (2017–2025)
This chart illustrates how Evaxion Biotech AS's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Evaxion Biotech AS worth.
Annual Net Assets for Evaxion Biotech AS (2017–2025)
The table below shows the annual net assets of Evaxion Biotech AS from 2017 to 2025. Also explore net asset momentum of Evaxion Biotech AS to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $17.04 Million | +1131.40% |
| 2024-12-31 | $-1.65 Million | +65.07% |
| 2023-12-31 | $-4.73 Million | -156.96% |
| 2022-12-31 | $8.30 Million | -74.40% |
| 2021-12-31 | $32.44 Million | +360.88% |
| 2020-12-31 | $7.04 Million | -24.82% |
| 2019-12-31 | $9.36 Million | +1105.59% |
| 2018-12-31 | $-931.00K | -136.51% |
| 2017-12-31 | $2.55 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Evaxion Biotech AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12272891700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $15.79 Million | 92.68% |
| Other Comprehensive Income | $6.76 Million | 39.68% |
| Other Components | $120.73 Million | 708.56% |
| Total Equity | $17.04 Million | 100.00% |
Evaxion Biotech AS Competitors by Market Cap
The table below lists competitors of Evaxion Biotech AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Argent Minerals Ltd
AU:ARD
|
$27.71 Million |
|
Connexa Sports Technologies Inc.
NASDAQ:YYAI
|
$27.72 Million |
|
Hidropar Hareket Kontrol Teknolojileri Merkezi Sanayi ve Ticaret A.S.
IS:HKTM
|
$27.73 Million |
|
DIAMINES AND CHEMICALS ORD (BSE)
NSE:DIAMINESQ
|
$27.73 Million |
|
UMediC Group Berhad
KLSE:0256
|
$27.69 Million |
|
Park Street A/S
CO:PARKST-A
|
$27.68 Million |
|
Kyobo 8 Special Purpose Acquisition Company
KQ:307280
|
$27.68 Million |
|
Avalon Advanced Materials Ltd
TO:AVL
|
$27.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Evaxion Biotech AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,652,000 to 17,038,718, a change of 18,690,718.
- Net loss of 7,707,000 reduced equity.
- New share issuances of 23,161,000 increased equity.
- Other comprehensive income increased equity by 10,355,888.
- Other factors decreased equity by 7,119,170.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.71 Million | -45.23% |
| Share Issuances | $23.16 Million | +135.93% |
| Other Comprehensive Income | $10.36 Million | +60.78% |
| Other Changes | $-7.12 Million | -41.78% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Evaxion Biotech AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.15x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 19.50x to 1.15x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.16 | $3.07 | x |
| 2018-12-31 | $-1.94 | $3.07 | x |
| 2019-12-31 | $23.12 | $3.07 | x |
| 2020-12-31 | $17.38 | $3.07 | x |
| 2021-12-31 | $66.56 | $3.07 | x |
| 2022-12-31 | $14.05 | $3.07 | x |
| 2023-12-31 | $-6.92 | $3.07 | x |
| 2024-12-31 | $-1.54 | $3.07 | x |
| 2025-12-31 | $2.66 | $3.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Evaxion Biotech AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -45.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -102.38%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.67x
- Recent ROE (-45.23%) is above the historical average (-91.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.44 Million |
| 2019 | -119.56% | 0.00% | 0.00x | 1.18x | $-12.13 Million |
| 2020 | -213.38% | 0.00% | 0.00x | 1.70x | $-15.72 Million |
| 2021 | -75.63% | 0.00% | 0.00x | 1.24x | $-27.78 Million |
| 2022 | -279.04% | 0.00% | 0.00x | 2.65x | $-24.00 Million |
| 2023 | 0.00% | -30308.22% | 0.01x | 0.00x | $-21.65 Million |
| 2024 | 0.00% | -316.00% | 0.27x | 0.00x | $-10.40 Million |
| 2025 | -45.23% | -102.38% | 0.27x | 1.67x | $-9.41 Million |
Industry Comparison
This section compares Evaxion Biotech AS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Evaxion Biotech AS (EVAX) | $9.53 Million | 0.00% | 1.03x | $27.70 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About Evaxion Biotech AS
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid le… Read more